近日,武田制药被判向一位美国妇女支付200万美元损害赔偿。该妇女称受到武田糖尿病药物吡格列酮损害,并表示该药物导致她患上膀胱癌,但武田争论称吸烟是更可能的因素。此外,成千上万指控受吡格列酮损害的诉讼正等待去审判。这次裁决之前,路易斯安那州一家法院在认定武田制药与其前联合销售合作伙伴礼来掩盖了与该药物使用相关的癌症风险之后,判定两家公司支付90亿美元的惩罚性赔偿。8月份,礼来与武田未能推翻惩罚性赔 Recently, Takeda Pharmaceutical was awarded a U.S. woman $ 2 million damages. The woman claimed to have been damaged by the Tiapia diabetes drug pioglitazone and said the drug caused her to develop bladder cancer but Takeda argued that smoking was a more likely factor. In addition, tens of thousands of claims alleging damage by pioglitazone are pending trial. Prior to the ruling, a Louisiana court ruled that both companies had paid $ 9 billion in punitive damages after finding that Takeda Pharmaceutical and its former co-sales partner Eli Lilly overshadowed the cancer risk associated with the use of the drug. In August, Lilly and Takeda failed to overthrow the punitive damages